The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 501–600 of 1,001
Proteomic studies on apoB-containing lipoprotein in cardiovascular research: A comprehensive review.
Gianazza, E., Zoanni, B., Mallia, A., Brioschi, M., Colombo, G., & Banfi, C. (2021) · Mass spectrometry reviews (Print) · doi:10.1002/mas.21747 · Cited by 10
HDL and Cholesterol Ester Transfer Protein (CETP)
Deng, S., Liu, J., & Niu, C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_2 · Cited by 14
Rahman, F., Blumenthal, R. S., Jones, S. R., Martin, S. S., Gluckman, T. J., & Whelton, S. P. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0713-2 · Cited by 15
Kobayashi, D., Noto, H., Shimbo, T., Ino, T., Osugi, Y., Takahashi, O., & Asai, K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.918 · Cited by 14
Discovering Biological Mechanisms of Exceptional Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041204 · Cited by 14
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 13
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Liao, K. P., Rist, P. M., Giles, J. T., Santacroce, L. M., Connelly, M. A., Glynn, R. J., Ridker, P. M., Tawakol, A. A., Bathon, J. M., & Solomon, D. H. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03352-3 · Cited by 14
Nicholls, S. J., Nelson, A. J., Kastelein, J. J. P., Ditmarsch, M., Hsieh, A., Johnson, J., Curcio, D. L., Kling, D. F., Kirkpatrick, C. F., & Davidson, M. H. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70010 · Cited by 13
Okada, T., Ohama, T., Okazaki, M., Kanno, K., Matsuda, H., Sairyo, M., Zhu, Y., Saga, A., Kobayashi, T., Masuda, D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190875 · Cited by 13
Dyslipidemia and atherosclerotic carotid artery stenosis
Miura, Y., & Suzuki, H. (2019) · Vessel Plus · doi:10.20517/2574-1209.2018.69 · Cited by 13
Reduced CETP glycosylation and activity in patients with homozygous B4GALT1 mutations
van den Boogert, M. A. W., Crunelle, C. L., Ali, L., Larsen, L. E., Kuil, S. D., Levels, J. H. M., Schimmel, A. W. M., Konstantopoulou, V., Guérin, M., Kuivenhoven, J. A., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12200 · Cited by 13
Babadagli, H. E., Barry, A. R., Thanassoulis, G., & Pearson, G. J. (2023) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635231164989 · Cited by 12
The Imminent Demise of Cardiovascular Drug Development
Packer, M. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3753 · Cited by 13
Packard, C. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1003-x · Cited by 13
Is hypertriglyceridemia atherogenic?
Roubille, F., Sultan, A., Huet, F., Leclercq, F., Macia, J., Gervasoni, R., Delseny, D., Akodad, M., & Roubille, C. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.08.009 · Cited by 13
Allard‐Ratick, M., Sandesara, P. B., Quyyumi, A. A., & Sperling, L. S. (2019) · US Cardiology Review · doi:10.15420/usc.2019.3.2 · Cited by 13
Koh, E. S., Kim, M.-Y., Kim, M. K., Han, K., Shin, S. J., Kwon, H., Park, C. W., Park, Y. G., & Chung, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.018 · Cited by 13
Endovascular Aneurysm Sealing is Associated with Higher Medium-Term Survival than Traditional EVAR
O’Donnell, T. F. X., Carpenter, J. P., Lane, J. S., Trani, J., Hussain, S., Healey, C., Malas, M. B., & Schermerhorn, M. L. (2019) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2019.08.094 · Cited by 13
Management of Hyperlipidemia After Stroke
Brooks, D. C., & Schindler, J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0774-8 · Cited by 13
Burgess, S., Foley, C. N., Allara, E., Staley, J. R., & Howson, J. M. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/566851 · Cited by 13
HDL metabolism and function in diabetes mellitus
Cochran, B. J., King, T. W., Chemello, K., Thomas, S. R., & Rye, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01176-y · Cited by 15
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04179-4 · Cited by 12
de Winter, N., Ji, J., Sintou, A., Forte, E., Lee, M., Noseda, M., Li, A., Koenig, A. L., Lavine, K. J., Hayat, S., et al. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.04.016 · Cited by 12
McCarthy, C. P., Ballantyne, C. M., Blankstein, R., Budoff, M. J., Ditmarsch, M., Gibson, C. M., Kastelein, J. J. P., Návar, A. M., Nicholls, S. J., Ray, K. K., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.07.012 · Cited by 12
Christen, T., Trompet, S., Noordam, R., Blauw, L. L., Gast, K. B., Rensen, P. C. N., van Dijk, K. W., Rosendaal, F. R., de Mutsert, R., & Jukema, J. W. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.023 · Cited by 12
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk
Barter, P. J., & Rye, K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.011 · Cited by 12
Implications for REDUCE IT in clinical practice
Bittner, V. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.003 · Cited by 12
Chen, C., Sun, R., Sun, Y., Chen, X., Li, F., Wen, X., Yuan, H., & Chen, D. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126824 · Cited by 12
Tackling cardiometabolic risk in the Asia Pacific region
Li, J., Yeo, K. K., Tan, K., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., Dalal, J. J., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100096 · Cited by 13
Colombo, G. I., Bianconi, V., Bonomi, A., Simonelli, S., Amato, M., Frigerio, B., Ravani, A. L., Vitali, C., Sansaro, D., Coggi, D., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030286 · Cited by 12
Unraveling the Complexity of HDL Remodeling: On the Hunt to Restore HDL Quality
Schoch, L., Badimón, L., & Vilahur, G. (2021) · Biomedicines · doi:10.3390/biomedicines9070805 · Cited by 12
Khalaf, R. A., Awad, M., Al‐Qirim, T. M., & Sabbah, D. A. (2021) · Medicinal Chemistry · doi:10.2174/1573406417666210830125431 · Cited by 12
Liu, L., Sheng, C., Lyu, Z., Dai, H., & Chen, K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.755834 · Cited by 12
Zhu, L., An, J., Chinnarasu, S., Luu, T. N., Pettway, Y. D., Fahey, K., Litts, B., Kim, H., Flynn, C. R., Linton, M. F., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.799096 · Cited by 12
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I
Thomas, S. R., Zhang, Y., & Rye, K. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101689 · Cited by 12
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Guan, X., Shi, H.-P., Xu, S., Chen, Y., Zhang, R.-F., Dong, Y., Gao, L., Wu, S., & Xia, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1105342 · Cited by 12
Conditional Inference in Cis-Mendelian Randomization Using Weak Genetic Factors
Patel, A., Gill, D., Newcombe, P. J., & Burgess, S. (2023) · Biometrics · doi:10.1111/biom.13888 · Cited by 12
ANGPTL3 is a novel HDL component that regulates HDL function
Yang, L., Wang, Y., Xu, Y., Li, K., Yin, R., Zhang, L., Wang, D., Wei, L., Lang, J., Cheng, Y., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05032-x · Cited by 13
Comparing the effects of CETP in East Asian and European ancestries: a Mendelian randomization study
Dunca, D., Chopade, S., Gordillo‐Marañón, M., Hingorani, A. D., Kuchenbaecker, K. B., Finan, C., & Schmidt, A. F. (2023) · Nature Communications · doi:10.1016/j.atherosclerosis.2023.06.880 · Cited by 12
Nádró, B., Juhász, L., Szentpéteri, A., Páll, D., Paragh, G., & Harangi, M. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.30980 · Cited by 12
Treating Dyslipidemia in Type 2 Diabetes
Nelson, A. J., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.005 · Cited by 13
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Lee, S., & Cannon, C. P. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0997-4 · Cited by 12
Inheritance of high and low HDL: mechanisms and management
Sourlas, A., & Kosmas, C. E. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000610 · Cited by 13
Srisawasdi, P., Rodcharoen, P., Vanavanan, S., Chittamma, A., Sukasem, C., Nakorn, C. N., Dejthevaporn, C., & Kroll, M. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s278671 · Cited by 13
Arai, H., Bujo, H., Masuda, D., Ishibashi, T., Nakagawa, S., Tanabe, K., Kagimura, T., Kang, H., Kim, M. H., Sung, J., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62821 · Cited by 13
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Marouf, B. H., Iqbal, Z., Mohamad, J. B., Bashir, B., Schofield, J. D., Syed, A. A., Kilpatrick, E. S., Stefanutti, C., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.12.005 · Cited by 12
Macular Degeneration and CETP Inhibition
Tall, A. R., Rader, D. J., & Kastelein, J. J. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1276 · Cited by 12
Katamine, M., Minami, Y., & Ako, J. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22044 · Cited by 12
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Uribe, K. B., Benito‐Vicente, A., Martı́n, C., Blanco‐Vaca, F., & Rotllán, N. (2021) · Biomaterials Science · doi:10.1039/d0bm01838d · Cited by 14
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development
Davidson, M. H., Hsieh, A., Dicklin, M. R., & Maki, K. C. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.12.005 · Cited by 14
Leveraging Mendelian randomization to inform drug discovery and development for ischemic stroke
Daghlas, I., & Gill, D. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241305916 · Cited by 11
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence
Bhatti, M. I., Safiullah, M., Farhan, K., Ali, A., Abdullah, S., Ali, A., & Ahmed, R. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.003 · Cited by 11
Barbosa, C., Maranhão, R. C., Barreiros, R. S., Freitas, F. R., Franci, A., Strunz, C. M. C., Arantes, F. B. B., Tavoni, T. M., Ramires, J. A. F., Filho, R. K., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23259 · Cited by 11
Johns, D. G., Wang, S., Rosa, R. L., Hubert, J. A., Xu, S. S., Chen, Y., Bateman, T. J., & Blaustein, R. O. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.543 · Cited by 12
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
Rhainds, D., Packard, C. J., Brodeur, M. R., Niesor, E. J., Sacks, F. M., Jukema, J. W., Wright, R. S., Waters, D. D., Heinonen, T. M., Black, D. M., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003219 · Cited by 11
Kang, I., Park, M.-Y., Yang, S. J., & Lee, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123057 · Cited by 11
Reducing residual cardiovascular risk with novel therapies
Davidson, M. H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000672 · Cited by 11
Risk factors for cardiovascular disease in the Chinese population: recent progress and implications
Pang, Y., Lyu, J., Yu, C., Guo, Y., & Lee, L. (2020) · Global Health Journal · doi:10.1016/j.glohj.2020.08.004 · Cited by 11
Li, W., Liu, X., Huang, C., Liu, L., Tan, X., & Wang, X. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.10.019 · Cited by 12
Araújo, B., Arrighini, G. S., Queiroga, F., Mansouri, E. S., Rivera, A., Amador, W. F. O., Queiroz, I., Akabane, M. A. C. C., Consoli, L. N., Sobral, M. V. S., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101303 · Cited by 10
Lipoprotein(a)-lowering therapies: a promising future
Zhang, J., Návar, A. M., & Tokgözoğlu, L. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag092 · Cited by 13
Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It
Tuka, V., Holub, J., & Bělohlávek, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306210 · Cited by 13
High density lipoprotein as a therapeutic target: Focus on its functionality
Rosso, L. A. G., Davico, B., Chiappe, E. L., Tetzlaff, W., Boero, L. E., Brites, F. D., & Martín, M. (2023) · Biocell · doi:10.32604/biocell.2023.031063 · Cited by 10
Phospholipid biomarkers of coronary heart disease
Morita, S. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00344-y · Cited by 10
Schmidt, A. F., Davidson, M. H., Ditmarsch, M., Kastelein, J. J. P., & Finan, C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01594-6 · Cited by 12
Distinct roles of size-defined HDL subpopulations in cardiovascular disease
Davidson, W. S., Vaisar, T., Heinecke, J. W., & Bornfeldt, K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000959 · Cited by 10
Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
Hu, W., Han, F., Liu, Y., Xu, X., Zhou, P., Sun, Z., Tao, X., Yang, J., Wu, J., Qu, C., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2462466 · Cited by 10
HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications
Stoicescu, C. I., Văcărescu, C., & Cozma, D. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144945 · Cited by 11
Lipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 10
Hou, J., Deng, Q., Liu, S., Qiu, X., Deng, X., Zhong, W. H., & Zhong, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.793405 · Cited by 10
HDL as Bidirectional Lipid Vectors: Time for New Paradigms
Luna‐Luna, M., Niesor, E. J., & Pérez-Méndez, O. A. (2022) · Biomedicines · doi:10.3390/biomedicines10051180 · Cited by 11
Trius‐Soler, M., Mukamal, K. J., & Guasch‐Ferré, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000906 · Cited by 10
Chen, H., Zhou, X., Hu, J., Li, S., Wang, Z., Zhu, T., Cheng, H., & Zhang, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01983-0 · Cited by 10
Zhou, J., Zhang, Q., Wang, Y., Gao, P., & Chen, D. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1401421 · Cited by 10
Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase
Johnson, J. A., Tora, G. O., Pi, Z., Phillips, M. S., Yin, X., Yang, R., Zhao, L., Chen, A. Y. A., Taylor, D. S., Basso, M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00424 · Cited by 10
A Journey through Genetic Architecture and Predisposition of Coronary Artery Disease
Roberts, R., & Chang, C. C. (2020) · Current Genomics · doi:10.2174/1389202921999200630145241 · Cited by 10
Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
Khan, I., Peterson, E. D., Cannon, C. P., Sedita, L. E., Edelberg, J. M., & Ray, K. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016506 · Cited by 10
Towards Personalized Therapy of Aortic Stenosis
Mazur, P. K., Kopytek, M., Ząbczyk, M., Undas, A., & Natorska, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121292 · Cited by 10
The Potential Clinical Benefit of Lowering Lipoprotein(a)
Ference, B. A. (2022) · JAMA · doi:10.1001/jama.2022.5333 · Cited by 10
Very low HDL levels: clinical assessment and management
Bonilha, I., Luchiari, B., Nadruz, W., & Sposito, A. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000585 · Cited by 12
Doğan, C., Bayram, Z., Karagöz, A., Bakal, R. B., Erdoğan, E., Yilmaz, F., Akbal, Ö. Y., Acar, R. D., Aktemur, T., Şengör, B. G., et al. (2019) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2018_140 · Cited by 10
Bandaru, M. K., Emmanouilidou, A., Ranefall, P., von der Heyde, B., Mazzaferro, E., Klingström, T., Masiero, M. M., Dethlefsen, O., Ledin, J., Larsson, A. O., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/502674 · Cited by 10
Hirsch, D. S., Lau, B., Kushwaha, V. V., & Yong, K. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2406181 · Cited by 10
Rajesh, K., Spring, K. J., Smokovski, I., Upmanyue, V., Mehndiratta, M. M., Strippoli, G. F., Beran, R. G., & Bhaskar, S. M. M. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02556-w · Cited by 11
The role of high-density lipoproteins in sepsis
Brunham, L. R. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100728 · Cited by 10
König, T., Berliner, D., Diekmann, J., Akin, M., Pfeffer, T. J., Martinez, C. S., Garcheva, V., Bengel, F. M., Bauersachs, J. K., & Schäfer, A. (2025) · EuroIntervention · doi:10.4244/eij-d-25-00034 · Cited by 10
High-density lipoprotein in cardiovascular diseases: From high quantity to high quality
Zhang, Y., Yu, M., Chen, Y., & Huang, J. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120574 · Cited by 10
Toth, P. P., Jones, S. R., Slee, A. E., Fleg, J. L., Marcovina, S. M., Lacy, M., McBride, R., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.077 · Cited by 9
High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 9
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad485 · Cited by 9
All we need to know about lipoprotein(a)
Bess, C., Mehta, A., & Joshi, P. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.007 · Cited by 9
Insights from population-based analyses of plasma lipids across the allele frequency spectrum
Peloso, G. M., & Natarajan, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.003 · Cited by 10
What have we learnt from the clinical outcomes trials with the cetrapibs?
Doggrell, S. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000518 · Cited by 9
Polygenic modelling of treatment effect heterogeneity
Xu, Z. M., & Burgess, S. (2020) · Genetic Epidemiology · doi:10.1002/gepi.22347 · Cited by 9
Recent advances and emerging therapies in management of dyslipidemias
Pulipati, V. P., & Davidson, M. H. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.08.007 · Cited by 9
Yamada, K., Brousseau, M. E., Honma, W., Iimura, A., Imase, H., Iwaki, Y., Kawanami, T., LaSala, D., Liang, G., Mitani, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00900 · Cited by 9
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
